Table 2:
Outcome; follow-up period, yr | Deaths/N | Biomarker; HR* (95% CI) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
Model 1† | Model 2‡ | Model 3§ | ||||||||
|
|
|
||||||||
AGP | IL-6 | CRP | AGP | IL-6 | CRP | AGP | IL-6 | CRP | ||
All-cause mortality | ||||||||||
| ||||||||||
Overall | 736/6545 | 1.18 (1.09–1.27) | 1.35 (1.26–1.44) | 1.27 (1.17–1.37) | 1.06 (0.97–1.15) | 1.25 (1.16–1.35) | 1.17 (1.07–1.27) | 0.99 (0.90–1.08) | 1.22 (1.12–1.33) | 1.07 (0.97–1.18) |
| ||||||||||
< 5 | 107/6545 | 1.43 (1.19–1.72) | 1.75 (1.49–2.06) | 1.65 (1.36–2.00) | 1.30 (1.06–1.59) | 1.61 (1.36–1.92) | 1.54 (1.25–1.90) | 1.09 (0.87–1.37) | 1.47 (1.20–1.81) | 1.18 (0.93–1.51) |
| ||||||||||
5–10 | 175/6438 | 1.24 (1.08–1.44) | 1.36 (1.18–1.56) | 1.28 (1.10–1.50) | 1.15 (0.98–1.34) | 1.28 (1.10–1.49) | 1.21 (1.02–1.43) | 1.06 (0.89–1.27) | 1.23 (1.04–1.46) | 1.06 (0.87–1.30) |
| ||||||||||
≥ 10 | 454/6263 | 1.09 (0.99–1.20) | 1.25 (1.14–1.37) | 1.18 (1.08–1.31) | 0.98 (0.88–1.09) | 1.15 (1.04–1.27) | 1.07 (0.96–1.20) | 0.93 (0.83–1.05) | 1.15 (1.03–1.28) | 1.04 (0.91–1.18) |
| ||||||||||
Cardiovascular mortality¶ | ||||||||||
| ||||||||||
Overall | 181/6541 | 1.27 (1.10–1.46) | 1.37 (1.19–1.57) | 1.51 (1.30–1.76) | 1.06 (0.90–1.24) | 1.19 (1.02–1.39) | 1.32 (1.12–1.57) | 0.94 (0.79–1.13) | 1.08 (0.90–1.29) | 1.30 (1.06–1.61) |
| ||||||||||
< 5 | 31/6543 | 1.44 (1.02–2.05) | 1.57 (1.14–2.16) | 1.56 (1.08–2.24) | 1.28 (0.87–1.87) | 1.34 (0.96–1.88) | 1.49 (1.00–2.22) | 1.11 (0.72–1.71) | 1.17 (0.78–1.76) | 1.28 (0.78–2.11) |
| ||||||||||
5–10 | 42/6436 | 1.32 (0.98–1.77) | 1.51 (1.15–1.99) | 1.63 (1.19–2.21) | 1.06 (0.76–1.48) | 1.36 (1.01–1.85) | 1.39 (0.99–1.97) | 0.92 (0.64–1.31) | 1.25 (0.87–1.79) | 1.28 (0.84–1.95) |
| ||||||||||
≥ 10 | 108/6263 | 1.20 (1.00–1.45) | 1.26 (1.04–1.51) | 1.45 (1.19–1.77) | 0.99 (0.81–1.22) | 1.07 (0.86–1.33) | 1.25 (1.00–1.57) | 0.91 (0.72–1.14) | 0.97 (0.76–1.24) | 1.32 (1.00–1.75) |
| ||||||||||
Cancer-related mortality¶ | ||||||||||
| ||||||||||
Overall | 347/6541 | 1.09 (0.98–1.22) | 1.25 (1.13–1.39) | 1.23 (1.11–1.38) | 0.99 (0.88–1.12) | 1.17 (1.04–1.30) | 1.15 (1.02–1.30) | 0.92 (0.81–1.06) | 1.13 (1.00–1.29) | 1.12 (0.97–1.29) |
| ||||||||||
< 5 | 54/6543 | 1.50 (1.17–1.91) | 1.66 (1.32–2.09) | 1.78 (1.37–2.33) | 1.35 (1.02–1.78) | 1.52 (1.18–1.97) | 1.64 (1.23–2.19) | 1.13 (0.83–1.53) | 1.30 (0.96–1.76) | 1.34 (0.95–1.90) |
| ||||||||||
5–10 | 87/6436 | 1.11 (0.90–1.38) | 1.21 (0.98–1.48) | 1.17 (0.94–1.46) | 1.01 (0.79–1.28) | 1.11 (0.88–1.40) | 1.07 (0.84–1.38) | 0.97 (0.75–1.27) | 1.09 (0.85–1.41) | 1.04 (0.78–1.39) |
| ||||||||||
≥ 10 | 206/6263 | 0.99 (0.85–1.15) | 1.17 (1.02–1.34) | 1.14 (0.99–1.32) | 0.90 (0.76–1.07) | 1.10 (0.95–1.28) | 1.08 (0.92–1.27) | 0.85 (0.71–1.02) | 1.10 (0.93–1.30) | 1.10 (0.91–1.34) |
Note: AGP = α1-acid glycoprotein, CI = confidence interval, CRP = C-reactive protein, HR = hazard ratio, IL-6 = interleukin-6.
Hazard ratios are per 1 standard deviation increase in the inflammatory biomarker.
Adjusted for age and sex.
Adjusted for all covariates (age, sex, socioeconomic status, body mass index, health behaviours and chronic disease).
Adjusted for all covariates and other inflammatory biomarkers.
Four participants with unknown cause of death were excluded from these analyses.